Table 3.

Secondary endpoints in study patients during hospitalization (Turku University Hospital, Finland)

	Tocilizumab group (n = 57)	Standard-of-care group (n = 29)	p-value
Hospitalization (d), median (interquartile range)	9 (7–12)	12 (9–15)	0.014
Oxygen supplementation (d), median (interquartile range)	6 (3–8)	6.5 (3.5–10)	0.54
Incidence of treatment in ICU in patients not in ICU at baseline, n (%)	4 of 50 (8.0)	4 of 25 (16.0)	0.43
Duration of ICU stay (d), median (interquartile range)a	6 (4–12) n = 11 (19.3%)	5 (3.5–24) n = 8 (27.6%)	0.54
Incidence of IMV in patients not on IMV at baseline, n (%)	5 of 57 (8.8)	3 of 28 (10.7)	1.0
Duration of IMVb (d), median (interquartile range)	11 (10–19) n = 5	20.5 (10–29.5) n = 4	0.42
Death at day 28, n (%)	1 (1.8)	0 (0)	N/A

ICU, intensive care unit; IMV, invasive mechanical ventilation; N/A, not applicable.

^aCalculated only among patients admitted to ICU.

^bCalculated only among patients who were intubated.